Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis

Ramya Ramaswami, Marcos Daniel Villarreal, Dina Marie Pitta, Janet Carpenter, Justin Stebbing, Bindu Kalesan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Toxicity due to treatment causes a negative impact on quality of life in breast cancer survivors. Hot flash symptoms, described as intense sensations of heat, sweating and flushing occur in more than 50 % of breast cancer patients taking tamoxifen. We hypothesized that venlafaxine, a selective-norepinephrine reuptake inhibitor drug, was effective for reducing patient-reported hot flash scores among women treated for breast cancer compared to other non-hormonal treatments. We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. The primary outcome was hot flash score (derived from patient-reported hot flash severity and frequency) in randomized controlled trials. Standardized mean differences (SMD) were calculated for each study due to variation in the outcome measures. Heterogeneity was determined using I2 statistics, and publication bias was assessed using a contour funnel plot and Egger’s tests. Pooled analyses demonstrated that venlafaxine significantly reduced hot flash scores compared to the trial comparators (overall SMD 2.06; 95 % confidence interval (CI) [0.40, 3.72]). There was significant heterogeneity among these studies (I2 = 98.7 %, P 

Original languageEnglish (US)
Pages (from-to)231-237
Number of pages7
JournalBreast Cancer Research and Treatment
Volume152
Issue number2
DOIs
StatePublished - Jul 1 2015

Fingerprint

Hot Flashes
Meta-Analysis
Breast Neoplasms
Publication Bias
Sweating
Tamoxifen
Survivors
Venlafaxine Hydrochloride
Norepinephrine
Therapeutics
Randomized Controlled Trials
Hot Temperature
Quality of Life
Outcome Assessment (Health Care)
Confidence Intervals
Pharmaceutical Preparations

Keywords

  • Breast cancer
  • Hot flash
  • Meta-analysis
  • Review
  • Symptoms
  • Venlafaxine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Venlafaxine in management of hot flashes in women with breast cancer : a systematic review and meta-analysis. / Ramaswami, Ramya; Villarreal, Marcos Daniel; Pitta, Dina Marie; Carpenter, Janet; Stebbing, Justin; Kalesan, Bindu.

In: Breast Cancer Research and Treatment, Vol. 152, No. 2, 01.07.2015, p. 231-237.

Research output: Contribution to journalArticle

Ramaswami, Ramya ; Villarreal, Marcos Daniel ; Pitta, Dina Marie ; Carpenter, Janet ; Stebbing, Justin ; Kalesan, Bindu. / Venlafaxine in management of hot flashes in women with breast cancer : a systematic review and meta-analysis. In: Breast Cancer Research and Treatment. 2015 ; Vol. 152, No. 2. pp. 231-237.
@article{7fd387a1034e477598347bfc2303fd7e,
title = "Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis",
abstract = "Toxicity due to treatment causes a negative impact on quality of life in breast cancer survivors. Hot flash symptoms, described as intense sensations of heat, sweating and flushing occur in more than 50 {\%} of breast cancer patients taking tamoxifen. We hypothesized that venlafaxine, a selective-norepinephrine reuptake inhibitor drug, was effective for reducing patient-reported hot flash scores among women treated for breast cancer compared to other non-hormonal treatments. We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. The primary outcome was hot flash score (derived from patient-reported hot flash severity and frequency) in randomized controlled trials. Standardized mean differences (SMD) were calculated for each study due to variation in the outcome measures. Heterogeneity was determined using I2 statistics, and publication bias was assessed using a contour funnel plot and Egger’s tests. Pooled analyses demonstrated that venlafaxine significantly reduced hot flash scores compared to the trial comparators (overall SMD 2.06; 95 {\%} confidence interval (CI) [0.40, 3.72]). There was significant heterogeneity among these studies (I2 = 98.7 {\%}, P ",
keywords = "Breast cancer, Hot flash, Meta-analysis, Review, Symptoms, Venlafaxine",
author = "Ramya Ramaswami and Villarreal, {Marcos Daniel} and Pitta, {Dina Marie} and Janet Carpenter and Justin Stebbing and Bindu Kalesan",
year = "2015",
month = "7",
day = "1",
doi = "10.1007/s10549-015-3465-5",
language = "English (US)",
volume = "152",
pages = "231--237",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Venlafaxine in management of hot flashes in women with breast cancer

T2 - a systematic review and meta-analysis

AU - Ramaswami, Ramya

AU - Villarreal, Marcos Daniel

AU - Pitta, Dina Marie

AU - Carpenter, Janet

AU - Stebbing, Justin

AU - Kalesan, Bindu

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Toxicity due to treatment causes a negative impact on quality of life in breast cancer survivors. Hot flash symptoms, described as intense sensations of heat, sweating and flushing occur in more than 50 % of breast cancer patients taking tamoxifen. We hypothesized that venlafaxine, a selective-norepinephrine reuptake inhibitor drug, was effective for reducing patient-reported hot flash scores among women treated for breast cancer compared to other non-hormonal treatments. We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. The primary outcome was hot flash score (derived from patient-reported hot flash severity and frequency) in randomized controlled trials. Standardized mean differences (SMD) were calculated for each study due to variation in the outcome measures. Heterogeneity was determined using I2 statistics, and publication bias was assessed using a contour funnel plot and Egger’s tests. Pooled analyses demonstrated that venlafaxine significantly reduced hot flash scores compared to the trial comparators (overall SMD 2.06; 95 % confidence interval (CI) [0.40, 3.72]). There was significant heterogeneity among these studies (I2 = 98.7 %, P 

AB - Toxicity due to treatment causes a negative impact on quality of life in breast cancer survivors. Hot flash symptoms, described as intense sensations of heat, sweating and flushing occur in more than 50 % of breast cancer patients taking tamoxifen. We hypothesized that venlafaxine, a selective-norepinephrine reuptake inhibitor drug, was effective for reducing patient-reported hot flash scores among women treated for breast cancer compared to other non-hormonal treatments. We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. The primary outcome was hot flash score (derived from patient-reported hot flash severity and frequency) in randomized controlled trials. Standardized mean differences (SMD) were calculated for each study due to variation in the outcome measures. Heterogeneity was determined using I2 statistics, and publication bias was assessed using a contour funnel plot and Egger’s tests. Pooled analyses demonstrated that venlafaxine significantly reduced hot flash scores compared to the trial comparators (overall SMD 2.06; 95 % confidence interval (CI) [0.40, 3.72]). There was significant heterogeneity among these studies (I2 = 98.7 %, P 

KW - Breast cancer

KW - Hot flash

KW - Meta-analysis

KW - Review

KW - Symptoms

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=84946488431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946488431&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3465-5

DO - 10.1007/s10549-015-3465-5

M3 - Article

C2 - 26067931

AN - SCOPUS:84946488431

VL - 152

SP - 231

EP - 237

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -